Optimal lymphadenectomy and adjuvant capecitabine boost survival for gallbladder cancer patients.

• Patients with ≥6 lymph nodes resected had a 68% lower risk of death compared to those with inadequate lymphadenectomy.
• Adjuvant capecitabine led to a 48% increase in disease-free survival and a 67% improvement in overall survival.

Use these findings to prioritize thorough lymphadenectomy and consider capecitabine for eligible patients to enhance surgical outcomes.

• Hepatic disease, T stage, and resection status significantly impacted survival, underscoring the need for careful patient selection.